The European Medicines Agency (EMA) announced on Tuesday that it will hold an extraordinary meeting on December 29 “at the latest” to decide whether to approve marketing vaccine against covid-19 developed by German BioNTech and American giant Pfizer.
“If the data presented is strong enough to reach conclusions about the quality, safety and efficacy of the vaccine, the EMA (…) will conclude its evaluation at an extraordinary meeting scheduled for no later than 29 December”, said European regulators.
Also read: Europe started December with a high number of infections and deaths from Covid-19
Earlier, the alliance between Pfizer and BioNTech laboratories had announced that they had submitted a conditional authorization request for their vaccine to the EMA. Covid-19 in the European Union.
Another meeting will be held between now and January 12 to examine the new entry-market demand by American laboratory Moderna for its vaccine, European regulators said in a separate statement.
cg / agv